Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983973 | 0.98 | CYP2D6 (0.41) | CYP2D6ATMTDP1LMNATSHR | |
| SCHEMBL11972631 | 0.98 | CYP2D6 (0.41) | CYP2D6ATMTDP1LMNATSHR | |
| SCHEMBL10567818 | 0.90 | CYP2D6 (0.47) | CYP2D6KDM4E | |
| SCHEMBL11501574 | 0.84 | LMNA (0.36) | ATMCARM1PRMT6PRMT8TDP1 | |
| SCHEMBL19466429 | 0.79 | CYP2D6 (0.38) | CYP2D6LMNA | |
| SCHEMBL3978411 | 0.79 | SMN1; SMN2 (0.43) | CYP2D6KDM4E | |
| SCHEMBL2904075 | 0.78 | HRH3 (0.33) | ATMCARM1PRMT6PRMT8TDP1 | |
| SCHEMBL12717852 | 0.77 | LMNA (0.38) | ATMCARM1PRMT6PRMT8TDP1 | |
| SCHEMBL12718302 | 0.75 | ALDH1A1 (0.37) | LMNATSHR | |
| SCHEMBL3272365 | 0.75 | ATM (0.34) | ATMCARM1PRMT6PRMT8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709646-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | claimed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | QUAN MIMI L | 2006-10-05 | — | — | US | claimed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.I. (IT) | 2025-08-14 | — | — | US | disclosed |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114929681-B | Bicyclic CX3CR1 receptor agonists | 德州大学系统董事会 | 2024-05-14 | — | — | CN | disclosed |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2024-05-09 | — | — | US | disclosed |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230257353-A1 | IONIZABLE LIPIDOIDS AND THEIR USES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257353-A1 | IONIZABLE LIPIDOIDS AND THEIR USES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-17 | — | — | US | disclosed |
| CN-114929681-A | Bicyclic CX3CR1 receptor agonists | 德州大学系统董事会 | 2022-08-19 | — | — | CN | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | QUAN MIMI L | 2006-10-05 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257353-A1 | IONIZABLE LIPIDOIDS AND THEIR USES | TTR, PYGL, FABP1 | CYP2D6 822/4885ATM 4272/4885CARM1 4194/4885 |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | CYP2D6 1786/4885ATM 1944/4885CARM1 4345/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CYP2D6 3534/4885ATM 2591/4885CARM1 3556/4885 |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | TFPI, F2, TFPI2 | CYP2D6 1581/4885ATM 2192/4885CARM1 4004/4885 |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | CYP2D6 1786/4885ATM 1944/4885CARM1 4345/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | CYP2D6 3534/4885ATM 2591/4885CARM1 3556/4885 |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | F12, F2, TFPI | CYP2D6 601/4885ATM 1666/4885CARM1 3882/4885 |
| US-11958839-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | CYP2D6 1786/4885ATM 1944/4885CARM1 4345/4885 |
| US-20240150332-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | CYP2D6 1786/4885ATM 1944/4885CARM1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.